KX 02

Drug Profile

KX 02

Alternative Names: KX-2361; KX02

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Guangzhou Xiangxue Pharmaceuticals; Roswell Park Cancer Institute
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma
  • No development reported Brain cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in China (PO)
  • 24 May 2017 Chinese FDA approves Xiangxue Pharmaceuticals' IND application for KX 02 in Glioblastoma
  • 18 Oct 2016 Xiangxue Pharmaceuticals files an IND application with the China FDA in China for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top